StocksFundsScreenerSectorsWatchlists
TGTX

TGTX - TG Therapeutics Inc Stock Price, Fair Value and News

14.17USD-0.59 (-4.00%)Market Closed

Market Summary

TGTX
USD14.17-0.59
Market Closed
-4.00%

TGTX Alerts

  • 1 major insider sales recently.

TGTX Stock Price

View Fullscreen

TGTX RSI Chart

TGTX Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

172.68

Price/Sales (Trailing)

9.36

EV/EBITDA

84.8

Price/Free Cashflow

-69.66

TGTX Price/Sales (Trailing)

TGTX Profitability

EBT Margin

5.59%

Return on Equity

7.9%

Return on Assets

3.84%

Free Cashflow Yield

-1.44%

TGTX Fundamentals

TGTX Revenue

Revenue (TTM)

233.7M

Rev. Growth (Yr)

54.9K%

Rev. Growth (Qtr)

-73.48%

TGTX Earnings

Earnings (TTM)

12.7M

Earnings Growth (Yr)

72.8%

Earnings Growth (Qtr)

-112.65%

Breaking Down TGTX Revenue

Last 7 days

-2.4%

Last 30 days

-9.9%

Last 90 days

-10.1%

Trailing 12 Months

-29.7%

How does TGTX drawdown profile look like?

TGTX Financial Health

Current Ratio

5.92

Debt/Equity

0.62

Debt/Cashflow

-0.31

TGTX Investor Care

Shares Dilution (1Y)

5.51%

Diluted EPS (TTM)

0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20238.6M24.1M189.8M233.7M
20227.9M7.0M5.0M2.8M
2021907.0K2.4M4.4M6.7M
2020152.0K152.0K152.0K152.0K
2019337.0K152.0K152.0K152.0K
2018224.8K297.5K370.3K443.0K
2017283.1K240.5K231.5K152.0K
2016229.4K290.5K322.5K323.0K
201586.9K118.8K150.7K182.6K
201436.9K42.9K49.0K55.0K
201353.5K87.5K120.6K30.8K
201200092.1K
20100000
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of TG Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 13, 2024
lonial sagar
sold
-79,675
15.935
-5,000
-
Mar 12, 2024
charney laurence n
sold
-351,340
15.97
-22,000
-
Jan 06, 2024
weiss michael s
acquired
-
-
1,001,910
ceo
Jan 05, 2024
power sean a
acquired
-
-
75,000
cfo
Jan 05, 2024
charney laurence n
sold
-333,025
19.03
-17,500
-
Jan 03, 2024
power sean a
sold
-809,431
16.91
-47,867
cfo
Dec 15, 2023
power sean a
gifted
-
-
-40,000
cfo
Sep 28, 2023
hoberman kenneth
acquired
-
-
20,000
-
Sep 28, 2023
echelard yann
acquired
-
-
20,000
-
Sep 28, 2023
lonial sagar
sold
-
-
-20,000
-

1–10 of 50

Which funds bought or sold TGTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
Capital CS Group, LLC
unchanged
-
-32,772
266,555
0.25%
Apr 10, 2024
DAYMARK WEALTH PARTNERS, LLC
added
74.07
126,855
357,435
0.02%
Apr 10, 2024
Trust Co of the South
unchanged
-
-19,822
161,226
0.04%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
added
55.79
325,352
1,165,330
-%
Apr 05, 2024
Somerset Trust Co
unchanged
-
-18,700
152,100
0.06%
Apr 05, 2024
GAMMA Investing LLC
unchanged
-
-51.00
761
-%
Apr 05, 2024
CWM, LLC
added
3.81
-16,000
193,000
-%
Apr 05, 2024
NBC SECURITIES, INC.
reduced
-91.23
-148,000
12,000
-%
Mar 28, 2024
Newbridge Financial Services Group, Inc.
reduced
-8.48
38,232
82,189
0.04%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-1.72
29,853
59,473
-%

1–10 of 42

Are Funds Buying or Selling TGTX?

Are funds buying TGTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TGTX
No. of Funds

Unveiling TG Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
darwin global management, ltd.
2.7%
4,046,598
SC 13G/A
Feb 13, 2024
vanguard group inc
9.03%
13,670,944
SC 13G/A
Jan 26, 2024
blackrock inc.
7.1%
10,768,163
SC 13G/A
Jan 25, 2024
state street corp
5.45%
8,253,573
SC 13G/A
Apr 03, 2023
darwin global management, ltd.
7.1%
10,451,241
SC 13G
Feb 09, 2023
vanguard group inc
10.67%
15,502,764
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 03, 2023
state street corp
7.17%
10,415,161
SC 13G/A
Feb 01, 2023
blackrock inc.
6.3%
9,132,890
SC 13G/A
Oct 11, 2022
vanguard group inc
10.15%
14,746,392
SC 13G/A

Recent SEC filings of TG Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 15, 2024
4
Insider Trading
Mar 13, 2024
4
Insider Trading
Mar 13, 2024
144
Notice of Insider Sale Intent
Mar 12, 2024
144
Notice of Insider Sale Intent
Feb 29, 2024
10-K
Annual Report
Feb 28, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
5
Insider Trading
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 26, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to TG Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

TG Therapeutics Inc News

Latest updates
Yahoo Movies UK14 hours ago
Investor's Business Daily28 Feb 202408:00 am
The Motley Fool5 months ago

TG Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-73.5%43,970,500165,815,00016,074,0007,803,00080,00095,000594,0002,016,0002,321,0002,030,0001,545,000793,00038,00038,00038,00038,00038,00038,00038,00038,00038,000
Costs and Expenses10.6%56,456,00051,031,000---35,057,000---------------
Operating Expenses---60,748,00044,795,00052,143,00035,057,00039,535,00068,888,00095,269,00087,158,00079,036,00089,995,00086,820,00085,760,00050,883,00050,283,00037,998,00060,899,00035,582,00034,727,00054,188,000
  S&GA Expenses-4.9%31,153,50032,769,00030,715,00028,068,00022,505,00014,254,00012,638,00020,609,00032,412,00034,899,00034,017,00026,762,00043,859,00035,296,00014,434,00014,261,0007,055,5002,914,0002,716,0002,342,0001,912,500
  R&D Expenses18.3%17,448,00014,753,00028,122,00015,870,00029,635,00020,801,00026,874,00048,042,00062,646,50051,967,00044,871,00063,094,00042,961,00050,464,00036,449,00036,022,00030,943,50057,985,00032,866,00032,385,00052,275,500
EBITDA Margin-0.11--0.55-1.60-4.98-3.11-2.33-2.23-2.76-4.14-7.34-18.90-117--------
Interest Expenses-34.5%2,431,0003,713,0003,627,0002,844,0002,862,0001,648,0003,017,0002,664,0001,079,0001,038,0001,623,0001,898,0001,290,5001,610,0002,228,0001,201,0001,899,0001,537,0001,077,000774,000220,000
EBT Margin-0.06--1.01-2.84-8.74-4.85-3.50-3.08-3.64-5.53-10.09-26.85-160--------
Net Income-112.7%-14,416,000113,930,000-47,610,000-39,232,000-52,994,000-35,818,000-40,510,000-69,013,000-93,338,500-85,637,000-78,497,000-90,628,000-88,218,000-87,163,000-52,884,000-51,116,000-39,572,500-61,930,000-36,212,000-35,156,000-53,860,000
Net Income Margin139.7%0.05-0.14-7.30-19.66-71.22-47.49-41.44-41.26-52.04-77.84-142-351---------
Free Cashflow-Infinity%-13,210,000--42,008,000-59,905,000-23,873,000-34,499,000-49,116,000-68,696,000-86,989,000-67,280,000-60,344,000-81,422,000-52,181,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-0.4%33033122119719421825230338041048154962627429510216393.0010711884.00
  Current Assets-0.4%31831920918516818320324233137245553561226028188.0014980.0094.0010579.00
    Cash Equivalents-38.4%93.0015197.0061.0010211014718629932740247255325426152.0011445.0057.0064.0043.00
  Inventory18.7%40.0034.0030.0027.00-----------------
  Net PPE-28.6%0.000.000.000.000.000.000.001.001.001.001.000.000.000.000.000.000.000.000.000.000.00
  Goodwill0%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities1.7%16916618017013511712313314298.0098.0010310610310010312411993.0098.0060.00
  Current Liabilities-6.9%54.0058.0073.0063.0053.0036.0043.0055.0065.0088.0088.0092.0088.0078.0068.0063.0084.0080.0056.0061.0039.00
  Long Term Debt1.2%10099.0098.0097.0071.0071.0069.0067.0067.00---8.0015.0022.0029.0029.0029.0029.0028.00-
    LT Debt, Current---------1.0016.0023.0030.0022.0015.007.00------
    LT Debt, Non Current1.2%10099.0098.0097.0071.0071.0069.0067.0067.00---8.0015.0022.0029.0029.0029.0029.0028.00-
Shareholder's Equity-2.6%16116540.0027.0059.00100129170237312383445519171194-39.00-13.0019.0024.00
  Retained Earnings-1.0%-1,514-1,500-1,613-1,566-1,527-1,500-1,400-1,400-1,328-1,235-1,149-1,100-980-892-805-752-701-661600-563-528
  Additional Paid-In Capital0.6%1,6751,6651,6541,5941,5861,5751,5671,5681,5661,5471,5331,5171,5001,0631,000751740636613583553
Shares Outstanding0.0%151151151149146135135134132132132132---------
Float---3,400---564---4,936---2,163---688--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-115.8%-13,21083,704-42,005-59,902-23,870-34,495-49,116-68,689-86,909-67,201-60,169-81,355-52,026-56,532-43,834-62,115-30,393-33,202-35,860-33,351-33,690
  Share Based Compensation2.2%9,3859,18412,5416,82311,0587,000-1,0002,12114,35614,00016,30016,61833,50528,3007,40011,0686,4871,3008001,8821,454
Cashflow From Investing-48.1%-44,755-30,22930,501-6,16816,269-2,99010,379-43,6713,288-631-2,475-514-52,07614,91111,2051,4504.00-44.00457-1,135238
Cashflow From Financing-100.2%-1.0042147,04725,23849.00275135-85055,997-7,361-7,162-55.00403,38935,265241,09281.0098,35420,69528,28456,8804,694

TGTX Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Revenue$ 233,662$ 2,785$ 6,689
Costs and expenses:   
Cost of revenue14,131265790
Research and development:   
Noncash compensation13,01013,22424,047
Other research and development63,182112,128198,532
Total research and development76,192125,352222,579
Selling, general and administrative:   
Noncash compensation24,9235,96137,227
Other selling, general and administrative97,78364,04690,863
Total selling, general and administrative122,70670,007128,090
Total costs and expenses213,029195,624351,459
Operating income (loss)20,633(192,839)(344,770)
Other expense (income):   
Interest expense12,61510,1915,638
Other income(5,044)(4,695)(2,307)
Total other expense (income), net7,5715,4963,331
Net income (loss) before taxes13,062(198,335)(348,101)
Income taxes39000
Net income (loss)$ 12,672$ (198,335)$ (348,101)
Net income (loss) per common share:   
Basic (in dollars per share)$ 0.09$ (1.46)$ (2.63)
Diluted (in dollars per share)$ 0.09$ (1.46)$ (2.63)
Weighted-average shares outstanding:   
Basic (in shares)141,955,112135,411,258132,222,753
Diluted (in shares)148,508,465135,411,258132,222,753
Product [Member]   
Revenue:   
Revenue$ 92,005$ 2,633$ 6,537
License [Member]   
Revenue:   
Revenue$ 141,657$ 152$ 152

TGTX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Common stock, par value (in dollars per share)$ 0.001$ 0.001
Common stock, shares authorized (in shares)175,000,000175,000,000
Current assets:  
Cash and cash equivalents$ 92,933$ 102,304
Short-term investment securities124,57559,374
Accounts receivable, net51,0930
Inventories39,8230
Prepaid research and development4,1834,237
Other current assets5,3362,359
Total current assets317,943168,274
Restricted cash1,2851,273
Long-term investment securities012,404
Right of use assets8,0508,888
Leasehold interest, net1,4151,627
Equipment, net95307
Goodwill799799
Total assets329,587193,572
Current liabilities:  
Accounts payable and accrued expenses38,47142,019
Other current liabilities1,6311,169
Lease liability – current portion1,4461,581
Accrued compensation12,1728,432
Total current liabilities53,72053,201
Deferred revenue6,016305
Loan payable100,11871,135
Lease liability – non-current9,23110,344
Total liabilities169,085134,985
Commitments and contingencies
Stockholders’ equity:  
Common stock, $0.001 par value per share (175,000,000 shares authorized, 151,465,598 and 146,426,697 shares issued, 151,424,289 and 146,385,388 shares outstanding at December 31, 2023 and December 31, 2022, respectively151146
Additional paid-in capital1,674,9461,585,708
Treasury stock, at cost, 41,309 shares at December 31, 2023 and December 31, 2022(234)(234)
Accumulated deficit(1,514,361)(1,527,033)
Total stockholders’ equity160,50258,587
Total liabilities and stockholders’ equity$ 329,587$ 193,572
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
 CEO
 WEBSITEtgtherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES244

TG Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for TG Therapeutics Inc? What does TGTX stand for in stocks?

TGTX is the stock ticker symbol of TG Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TG Therapeutics Inc (TGTX)?

As of Fri Apr 12 2024, market cap of TG Therapeutics Inc is 2.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TGTX stock?

You can check TGTX's fair value in chart for subscribers.

What is the fair value of TGTX stock?

You can check TGTX's fair value in chart for subscribers. The fair value of TG Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TG Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TGTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TG Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TGTX is over valued or under valued. Whether TG Therapeutics Inc is cheap or expensive depends on the assumptions which impact TG Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TGTX.

What is TG Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, TGTX's PE ratio (Price to Earnings) is 172.68 and Price to Sales (PS) ratio is 9.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TGTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on TG Therapeutics Inc's stock?

In the past 10 years, TG Therapeutics Inc has provided 0.103 (multiply by 100 for percentage) rate of return.